Insight Molecular Diagnostics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.85, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Insight Molecular Diagnostics Inc in Jun 30 2026 quarter, has decreased to 95 days, compared to 96 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 442 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. 2959.

What is Receivable Turnover Ratio?
What is Insight Molecular Diagnostics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IMDX Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-62.5 %	-95.56 %	-30.07 %	23.44 %	502.35 %
Y / Y Revenue Change	-53.86 %	-98.5 %	-23.35 %	126.09 %	398.08 %
Receivable Turnover Ratio (TTM)	3.85	3.79	2.98	2.97	2.9
IMDX's Total Ranking	# 2959	# 2959	# 3091	# 2979	#
Accounts Receivable average collection period days	95	96	122	123	126
Seq. Receivable Change	22.29 %	-86.08 %	337.21 %	-49.61 %	-85.54 %
Seq. Revenue Change	646.88 %	-97.19 %	338.08 %	-49.81 %	-75.77 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 12
Healthcare Sector	# 443
Overall Market	# 2959

Receivable Turnover Ratio Statistics
High	Average	Low
7.36	3.29	0.95
(Dec 31 2020)		(Mar 31 2024)

IMDX Company Profile • Back to IMDX Efficiency Comparisons • Compare IMDX Receivables Turnover Ratio to its Competitors

Financial Statements
Insight Molecular Diagnostics Inc 's Accounts Receivable	$ 0 Millions	Visit IMDX's Balance sheet
Insight Molecular Diagnostics Inc 's Sales TTM	$ 2 Millions	Visit IMDX's Income Statement
Sources of IMDX's Revenues		Visit IMDX's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IMDX's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IMDX's Growth Rates	IMDX's Roa	IMDX's Inventory Turnover Ratio	IMDX's Dividend Comparisons
IMDX's Profitability Ratios	IMDX's Roi	IMDX's Asset Turnover Ratio	IMDX's Dividend Growth
IMDX's Valuation Ratios	IMDX's Roe	IMDX's Financial Strength Ratios	IMDX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Sonida Senior Living Inc	22.59	$ 525.973 Millions	$ 23.283 Millions
U S Physical Therapy Inc	22.40	$ 812.203 Millions	$ 36.251 Millions
Hims and Hers Health Inc	19.65	$ 2,578.494 Millions	$ 131.228 Millions
Lipocine Inc	18.36	$ 1.569 Millions	$ 0.085 Millions
Nrx Pharmaceuticals Inc	17.25	$ 3.394 Millions	$ 0.197 Millions
Polomar Health Services, Inc.	17.19	$ 3.172 Millions	$ 0.185 Millions
Anika Therapeutics Inc	16.70	$ 121.370 Millions	$ 7.266 Millions
Vireo Growth Inc.	16.69	$ 511.706 Millions	$ 30.659 Millions
Agenus Inc	15.44	$ 132.693 Millions	$ 8.595 Millions
Medicinova Inc	15.02	$ 0.920 Millions	$ 0.061 Millions
Dar Bioscience Inc	14.57	$ 1.345 Millions	$ 0.092 Millions
Nexgel Inc	14.52	$ 11.810 Millions	$ 0.813 Millions
China Pharma Holdings Inc	14.46	$ 3.914 Millions	$ 0.271 Millions
Lftd Partners Inc	14.13	$ 35.335 Millions	$ 2.500 Millions
Arvinas Inc	13.49	$ 316.700 Millions	$ 23.475 Millions
Corcept Therapeutics Inc	13.30	$ 830.813 Millions	$ 62.477 Millions
Precipio inc	13.25	$ 27.198 Millions	$ 2.052 Millions
Chemed Corporation	12.94	$ 2,595.001 Millions	$ 200.565 Millions
Petvivo Holdings Inc	12.34	$ 1.182 Millions	$ 0.096 Millions
Alpha Pro Tech Ltd	12.25	$ 62.204 Millions	$ 5.077 Millions
Vivos Therapeutics Inc	12.21	$ 21.135 Millions	$ 1.731 Millions
Milestone Scientific Inc	11.82	$ 8.855 Millions	$ 0.749 Millions
Marpai Inc	11.71	$ 16.635 Millions	$ 1.420 Millions
Catheter Precision Inc	11.62	$ 1.915 Millions	$ 0.165 Millions
Nrc Health	11.35	$ 139.996 Millions	$ 12.337 Millions
Picard Medical Inc	11.34	$ 5.983 Millions	$ 0.528 Millions
Veracyte Inc	11.07	$ 544.735 Millions	$ 49.194 Millions
International Stem Cell Corporation	10.91	$ 9.514 Millions	$ 0.872 Millions
Premier Air Charter Holdings Inc	10.66	$ 31.562 Millions	$ 2.961 Millions
Lifeloc Technologies Inc	10.48	$ 9.269 Millions	$ 0.884 Millions

Date modified: 2026-08-12T20:15:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.